ISAC

At MWC, InterDigital to Showcase Innovation Empowering Connected Experiences ‘At Work, At Rest, and At Play’

Retrieved on: 
Lunedì, Febbraio 19, 2024
HDR, Pixel, 2D, EVP, InterDigital, AI, Mobile, Research, Personal Touch, Keysight, 3D, Hall, Ink, Communication, Esports, Immersion, Rest, Mobile World Congress, Hertz, Partner, Education minister, Somatosensory system, ISAC, OTT, VVC, Work, Trade, MPEG, IDCC, Video game

“InterDigital innovation creates value through the tools we create and through the experiences they enable,” said Rajesh Pankaj, EVP and CTO at InterDigital.

Key Points: 
  • “InterDigital innovation creates value through the tools we create and through the experiences they enable,” said Rajesh Pankaj, EVP and CTO at InterDigital.
  • InterDigital is a long-time contributor to MPEG Immersive Standards, including Scene Description, V3C codecs alongside partner Philips, and newer haptics codecs to enable seamless, immersive experiences.
  • Elsewhere at MWC, InterDigital will lead stage presentations and showcase at partner booths to further amplify the impact of our research and innovation.
  • At the Keysight booth located at Hall 5 Stand 5E12, InterDigital and Keysight will together showcase a 144 GHz testbed utilizing an AI-enabled air interface.

Solutions for Testing Wireless, IP, Fiber Optics, Analog, and TDM Networks

Retrieved on: 
Lunedì, Gennaio 22, 2024
Voice over IP, EVS, Digital, GPS, ATM, API, Switch, NVM Express, Land mobile radio system, HDL, GSM, PPP, GTP, Noise, IP, Communication, Wide area network, SONET, Wireless, ITU, APS, Drive, CAMA, PESQ, Google Maps, Computer network, CAS, Phonation, ISDN, CLI, FXO, Voice over LTE, SMS, Human, SS7, Automation, TDM, RAW, RFC, Human voice, Data-rate units, OC-48, IUP, 3GPP, POLQA, GPRS, Language, Solid-state drive, INAP, TCP, ATA, MAP, Frame Relay, Optical fiber, Analog, AMR, HTTP, Estrone, ISAC, Mobile phone

“GL Communications Inc. is a leading test and measurement equipment manufacturer for Wireless, IP, Fiber Optic, Analog and TDM networks.

Key Points: 
  • “GL Communications Inc. is a leading test and measurement equipment manufacturer for Wireless, IP, Fiber Optic, Analog and TDM networks.
  • GL also offers consulting services to design, implement, verify, and inspect communications systems including wireless, IP, satellite, fiber optic, digital, and microwave networks.
  • GL offers multi-functional Ethernet testers to test individual devices such as cables, switches, routers, as well as end-to-end Ethernet/IP networks.
  • The test tools operate at wirespeed (1/10/25/40/50/100 Gbps) and offer bit error rate testing, RFC 2544, ITU-T Y.1564 and RFC 6349 based TCP testing.

5G Americas Explores 3GPP's Release 18 and Beyond in 5G-Advanced

Retrieved on: 
Mercoledì, Gennaio 10, 2024
5G, Telecommunications, Networks, Internet, Metaverse, Artificial Intelligence, Technology, Mobile, Wireless, Machine learning, Artificial intelligence, XR, 3GPP, AI, Communication, Human, ISAC, Integration, Redcap, Ericsson, Internet of things, Mobile phone

Today, 5G Americas, the voice of 5G and beyond in the Americas, has released a white paper titled ‘ 3GPP Technology Trends ’ which provides a detailed overview of the 3rd Generation Partnership Project (3GPP) and its journey towards 5G-Advanced that begins with Release 18 (NR Rel-18).

Key Points: 
  • Today, 5G Americas, the voice of 5G and beyond in the Americas, has released a white paper titled ‘ 3GPP Technology Trends ’ which provides a detailed overview of the 3rd Generation Partnership Project (3GPP) and its journey towards 5G-Advanced that begins with Release 18 (NR Rel-18).
  • Chris Pearson, President, 5G Americas said, "The enhancements brought forth in 3GPP Release 17, such as improved uplink coverage, precision in positioning, and robust power-saving features, signify more than just technological advancements.
  • They represent a leap towards a future where connectivity is both ubiquitous and seamlessly integrated into our daily lives."
  • The document underscores pivotal progressions in NR Rel-17, emphasizing their transformative effects on cellular networks and the wider technology arena.

Industrial Defender Joins the E-ISAC Vendor Affiliate Program

Retrieved on: 
Martedì, Gennaio 9, 2024
Gold, Lockheed Martin, Policy, Partnership, Electricity, Critical infrastructure protection, American Electric, NERC CIP, Industrial, Vendor, ISAC, NERC, Risk management

FOXBOROUGH, Mass., Jan. 9, 2024 /PRNewswire/ -- Industrial Defender, a pioneering leader in operational technology (OT) security and compliance, is proud to announce its new affiliation with the Electricity Information Sharing and Analysis Center (E-ISAC). Joining the E-ISAC's Vendor Affiliate Program as a Gold level member aligns with Industrial Defender's mission to bolster cybersecurity and compliance in the electricity sector across North America.

Key Points: 
  • Joining the E-ISAC's Vendor Affiliate Program as a Gold level member aligns with Industrial Defender's mission to bolster cybersecurity and compliance in the electricity sector across North America.
  • "Our partnership with E-ISAC represents an important milestone in our collaborative efforts with stakeholders in the electricity industry," said Jay Williams, CEO of Industrial Defender.
  • As a Gold level member of the E-ISAC Vendor Affiliate Program, Industrial Defender brings to the table its vast experience and expertise in OT asset management and compliance with the North American Electric Reliability Corporation (NERC) Critical Infrastructure Protection (NERC CIP) standards.
  • Industrial Defender's participation in the E-ISAC's Vendor Affiliate Program signals a strong commitment to enhancing information sharing and fostering collaboration between the electricity industry and vendor community.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Retrieved on: 
Martedì, Dicembre 5, 2023
ISAC, Neoplasm, Immunotherapy, HER2, Breast cancer, Trastuzumab, Roche, FC, Data, City, Research, Therapy, Publication, Pharmacokinetics, Clinical trial, Society, Bolt, MBC, Poster, Oncology, Pertuzumab, Patient, Safety, Assistant professor, Vaccine

The trial will treat patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®).

Key Points: 
  • The trial will treat patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®).
  • “Patients with HER2-positive breast cancer who progress after Enhertu have few therapeutic options,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.
  • “BDC-1001 has a unique mechanism of action compared to available agents, mobilizing the patient’s immune system to fight cancer.
  • Title: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan.

InterDigital’s Alain Mourad Elected Chair of New ETSI Industry Specification Group on Integrated Sensing and Communications (ISAC)

Retrieved on: 
Martedì, Novembre 21, 2023
Chalmers University of Technology, ISAC, Distributed ledger, Integration, InterDigital, Research, ETSI, Environment, XR, ISG, Privacy, IDCC, Radio, Orientation, UN, Communication, Renewable energy

WILMINGTON, Del., Nov. 21, 2023 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile and video technology research and development company, today announced that Dr. Alain Mourad, Head of InterDigital’s Wireless Lab Europe, has been elected Chair of the ETSI’s newly developed Industry Specification Group (ISG) on Integrated Sensing and Communication (ISAC).

Key Points: 
  • WILMINGTON, Del., Nov. 21, 2023 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile and video technology research and development company, today announced that Dr. Alain Mourad, Head of InterDigital’s Wireless Lab Europe, has been elected Chair of the ETSI’s newly developed Industry Specification Group (ISG) on Integrated Sensing and Communication (ISAC).
  • This enables the network to collect data on a plethora of device and object features, including range, velocity, position, orientation, size, shape, image, materials, and more.
  • “I’m delighted to lead the ISAC ISG for its inaugural two-year release.
  • “Alain’s strong leadership as the chair of the ETSI ISG on ISAC will provide a bedrock for enhanced capabilities and new use cases to explore in 6G,” said Rajesh Pankaj, Chief Technology Officer, InterDigital.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Novembre 9, 2023
Tumor-associated macrophage, Research, Annual general meeting, Renal cell carcinoma, Hereditary diffuse gastric cancer, Head, Colorectal cancer, ESMO, Administration, Patient, Triple-negative breast cancer, ASCO, MSK, FDA, Lung cancer, G&A, Immunotherapy, Patent, ORR, Ovarian cancer, MPH, Cancer, Trial of the century, Diagnosis, Nivolumab, SITC, Operation, Antibody, Research and development, R, Congress, Orphan, Society, TNBC, ISAC, NSCLC, Pharmaceutical industry, Vaccine, Cryptocurrency

Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.

Key Points: 
  • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.
  • Research and Development (R&D) Expenses – R&D expenses were $15.0 million for the quarter ended September 30, 2023, compared to $19.0 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.8 million for the quarter ended September 30, 2023, compared to $5.5 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.2 million for the quarter ended September 30, 2023, compared to $22.3 million for the same quarter in 2022.

KBRA Assigns Rating to AeBe ISA Ltd.

Retrieved on: 
Martedì, Novembre 21, 2023
Banking, Professional Services, Finance, KBRA, Risk management, American Energy Partners, LP, Risk, Outlook, Palm, Insurance, Bermuda Monetary Authority, GAAP, ISA, AUM, ISAC, AEB

KBRA assigns an A- insurance financial strength rating (IFSR) to AeBe ISA Ltd (AeBe), a Class E licensed Bermuda-based reinsurer that has GAAP total assets of approximately $4.4 billion as of June 30, 2023.

Key Points: 
  • KBRA assigns an A- insurance financial strength rating (IFSR) to AeBe ISA Ltd (AeBe), a Class E licensed Bermuda-based reinsurer that has GAAP total assets of approximately $4.4 billion as of June 30, 2023.
  • KBRA believes that the ISAC structure provides a robust corporate framework as well as operational flexibility to AeBe as the company onboards future business.
  • As AeBe executes its business plan, KBRA expects this ratio to decrease but remain strong over the medium term.
  • Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com .

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Retrieved on: 
Lunedì, Ottobre 23, 2023
CR, Memorial Sloan Kettering Cancer Center, PRS, Trastuzumab, Plasma, Cholangiocarcinoma, Aes, ESMO, ISAC, MPH, Nivolumab, Publication, HER2, Congress, LVEF, Salivary gland tumour, European Society for Medical Oncology, MSK, Phenotype, Pharmacodynamics, Bolt, Oncology, SDS, Cancer, Therapy, Patient, Breast, Toxicity, ASCO, TLR, Pharmaceutical industry, Vaccine

BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.

Key Points: 
  • BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.
  • The Phase 1 dose-escalation trial enrolled 131 patients with 16 different HER2-expressing solid tumor types across 18 dose levels in two arms, monotherapy and in combination with nivolumab.
  • The response rate at the RP2D was 29% in evaluable patients with HER2-positive tumors, both in monotherapy (2/7, 29%) and in combination with nivolumab (2/7, 29%).
  • Additionally, a copy of the presentation is available on the Publications page of the Bolt Therapeutics website.

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

Retrieved on: 
Mercoledì, Ottobre 18, 2023
Trastuzumab, Nivolumab, Publication, Society for Immunotherapy of Cancer, ISAC, Doctor of Philosophy, Research, Poster, SITC, San Diego Convention Center, Immunotherapy, Immune system, Annual general meeting, Pharmacology, Society, Cancer, Immunology, Patient, Vaccine, Pharmaceutical industry

Presentations will include trial-in-progress posters for ongoing clinical trials of BDC-1001, a HER2-targeting Boltbody™ ISAC, and BDC-3042, a novel Dectin-2 agonistic antibody

Key Points: 
  • Presentations will include trial-in-progress posters for ongoing clinical trials of BDC-1001, a HER2-targeting Boltbody™ ISAC, and BDC-3042, a novel Dectin-2 agonistic antibody
    REDWOOD CITY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will present four posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
  • The conference is being held at the San Diego Convention Center in San Diego, Calif. and virtually from November 1-5, 2023.
  • “Our research team has made significant progress across our portfolio, highlighting our commitment to generate breakthroughs for patients.
  • Additionally, a copy of each poster will be available on the Publications page of the Bolt Biotherapeutics website at the start of the poster session.